Immune infiltration and immune gene signature predict the response to fluoropyrimidine-based chemotherapy in colorectal cancer patients

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 [2018/September/13];68(6):394–15. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncolo: Official Journal of the European Society for Medical Oncology. 2016;27(8):1386–1422. doi:10.1093/annonc/mdw235.
   PubMed Web of Science ®Google Scholar
• Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet (London, England). 2007;370(9604):2020–2029. doi:10.1016/s0140-6736(07)61866-2.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncolo: Official Journal of the European Society for Medical Oncology. 2010 [2010/June/29];21(Suppl 5):v93–97. doi:10.1093/annonc/mdq222.
   PubMed Web of Science ®Google Scholar
• Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2019:107447. 2019/November/23 doi:10.1016/j.pharmthera.2019.107447.
   Google Scholar
• Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, FlynnMonika K. Krzyzanowska PJ, Maroun J, McAllister P, Cutsem EV, Brouwers M, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clinl Oncol: Official Journal of the American Society of Clinical Oncology. 2004 2004/June/17;22:3408–3419. doi:10.1200/jco.2004.05.063.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, Speers C, Cheung WY. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer. 2015 [2014/October/22];121(4):527–534. doi:10.1002/cncr.29072.
   PubMed Web of Science ®Google Scholar
• Chew V, Toh HC, Abastado JP. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol. 2012 2012/August/29;2012:608406. doi:10.1155/2012/608406.
   PubMedGoogle Scholar
• Pitt JM, Marabelle A, Eggermont A, Soria J-C, Kroemer G, Zitvogel  L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncolo: Official Journal of the European Society for Medical Oncology. 2016 2016/April/14;27:1482–1492. doi:10.1093/annonc/mdw168.
   PubMed Web of Science ®Google Scholar
• Brockhoff G, Seitz S, Weber F,  Zeman F, Klinkhammer-Schalke M, Olaf Ortmann O, Wege AK. The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease. Oncotarget. 2018 2018/February/22;9:6201–6212. doi:10.18632/oncotarget.23717.
   PubMedGoogle Scholar
• Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4+ T cells in the antitumor immune response. J Exp Med. 1998 [1998/December/22];188(12):2357–2368. doi:10.1084/jem.188.12.2357.
   PubMed Web of Science ®Google Scholar
• Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H, Ohuchi A, Ohuchi K, Shiiba K, Kurokawa Y, et al. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer. 2004;91(9):1711–1717. doi:10.1038/sj.bjc.6602201.
   PubMed Web of Science ®Google Scholar
• Mao Y, Feng Q, Zheng P, Yang L, Zhu D, Chang W, Ji M, He G, Xu J. Low tumor infiltrating mast cell density confers prognostic benefit and reflects immunoactivation in colorectal cancer. Intl J Cancer. 2018 [2018/June/07];143(9):2271–2280. doi:10.1002/ijc.31613.
   PubMed Web of Science ®Google Scholar
• Kocián P, Šedivcová M, Drgáč J, Černá K, Hoch J, Kodet R, Bartůňková J, Špíšek R, Fialová A. Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence. Hum Immunol. 2011 [2011/September/03];72(11):1022–1028. doi:10.1016/j.humimm.2011.07.312.
   PubMed Web of Science ®Google Scholar
• Saito T, Nishikawa H, Wada H,  Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016 2016/April/26;22:679–684. doi:10.1038/nm.4086.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Wang K Profiles of immune infiltration in colorectal cancer and their clinical significant: a gene expression-based study. 2018. DOI:10.1002/cam4.1745.
   Google Scholar
• Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol (Clifton, NJ). 2018 2018/January/19;1711:243–259. doi:10.1007/978-1-4939-7493-1_12.
   PubMedGoogle Scholar
• Yao Y, Yan Z, Lian S, Wei L, Zhou C, Feng D, Zhang Y, Yang J, Li M, Chen Y, et al. Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma. J Immunother Cancer. 2020;8(2):e000444. doi:10.1136/jitc-2019-000444.
   PubMed Web of Science ®Google Scholar
• Cao Y, He H, Li R, Liu X, Chen Y, Qi Y, Yu K, Wang J, Lin C, Liu H, et al. Latency-associated peptide identifies immunoevasive subtype gastric cancer with poor prognosis and inferior chemotherapeutic responsiveness. Ann Surg. 2020. Publish Ahead of Print. 2020/June/09 doi:10.1097/sla.0000000000003833.
   Google Scholar
• Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945. doi:10.1038/nm.3909.
   PubMed Web of Science ®Google Scholar
• Narayanan S, Kawaguchi T, Peng X, Qi Q, Liu S, Yan L, Takabe K. Tumor infiltrating lymphocytes and macrophages improve survival in microsatellite unstable colorectal cancer. Sci Rep. 2019 [2019/September/19];9(1):13455. doi:10.1038/s41598-019-49878-4.
   PubMed Web of Science ®Google Scholar
• Roelands J, Kuppen PJK, Vermeulen L, Maccalli C, Decock J, Wang E, Marincola F, Bedognetti D, Hendrickx W. Immunogenomic classification of colorectal cancer and therapeutic implications. Int J Mol Sci. 2017 [2017/October/25];18(10):2229. doi:10.3390/ijms18102229.
   PubMed Web of Science ®Google Scholar
• Ke J, Liu X-H, Jiang X-F, He Z, Xiao J, Zheng B, Chen Y-F, Cai Z-R, Zheng X-B, Zou Y-F, et al. Immune-related gene signature in predicting prognosis of early-stage colorectal cancer patients. Eur Jf Surgl Oncol: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2020;46(10):e62–e70. doi:10.1016/j.ejso.2020.08.008.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhao Y, Zhang J, Wu Q, Wang W. Development and validation of an immune-related gene pairs signature in colorectal cancer. Oncoimmunology. 2019 [2019/May/31];8(7):1596715. doi:10.1080/2162402x.2019.1596715.
   PubMed Web of Science ®Google Scholar
• Li Y, Liang L, Dai W, Cai G, Xu Y, Li X, Li Q, Cai S. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer. 2016 [2016/August/25];15(1):55. doi:10.1186/s12943-016-0539-x.
   PubMed Web of Science ®Google Scholar
• Fehlker M, Huska MR, Jons T, Andrade-Navarro MA, Kemmner W. Concerted down-regulation of immune-system related genes predicts metastasis in colorectal carcinoma. BMC Cancer. 2014 [2014/February/06];14(1):64. doi:10.1186/1471-2407-14-64.
   PubMed Web of Science ®Google Scholar
• Medler TR, Cotechini T, Coussens LM. Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends in Cancer. 2015 [2015/October/13];1(1):66–75. doi:10.1016/j.trecan.2015.07.008.
   PubMed Web of Science ®Google Scholar
• Opzoomer JW, Sosnowska D, Anstee JE, Spicer JF, Arnold JN. Cytotoxic chemotherapy as an immune stimulus: a molecular perspective on turning up the immunological heat on cancer. Front Immunol. 2019 2019/August/06;10:1654. doi:10.3389/fimmu.2019.01654.
   PubMed Web of Science ®Google Scholar
• Ali HR, Chlon L, Pharoah PD, Markowetz F, Caldas C. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med. 2016 [2016/December/14];13(12):e1002194. doi:10.1371/journal.pmed.1002194.
   PubMed Web of Science ®Google Scholar
• Schulz M, Salamero-Boix A, Niesel K, Alekseeva T, Sevenich L. Microenvironmental regulation of tumor progression and therapeutic response in brain metastasis. Front Immunol. 2019 2019/August/10;10:1713. doi:10.3389/fimmu.2019.01713.
   PubMed Web of Science ®Google Scholar
• Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019 [2019/June/04];12(1):54. doi:10.1186/s13045-019-0738-1.
   PubMed Web of Science ®Google Scholar
• Lal N, White BS, Goussous G, Pickles O, Mason MJ, Beggs AD, Taniere P, Willcox BE, Guinney J, Middleton GW, et al. KRAS mutation and consensus molecular subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer. Clin Cancer Res: An Official Journal of the American Association for Cancer Research. 2018;24(1):224–233. doi:10.1158/1078-0432.ccr-17-1090.
   PubMed Web of Science ®Google Scholar
• Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015 [2015/October/17];15(11):669–682. doi:10.1038/nri3902.
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong -K-K, Ziv E, et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019;7(1):131. doi:10.1186/s40425-019-0602-4.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Dunn P, Thomas CG, Smith B, Schaefer H, Chen J, Hu Z, Zalocusky KA, Shankar RD, Shen-Orr SS, et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data. 2018;5(1):180015. doi:10.1038/sdata.2018.15.
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, Zhong JY,  Zhong SSW,  Wu WC,  Chu KC,  Wong CY,  Lau CY, Chen I, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019. 2019/March/25 doi:10.1093/bioinformatics/btz210.
   Web of Science ®Google Scholar
• Fang Y, Yang C, Zhang L, Wei L, Lin J, Zhao J, Peng J. Spica prunellae extract enhances fluorouracil sensitivity of 5-fluorouracil-resistant human colon carcinoma HCT-8/5-FU cells via TOP2 α and miR-494. Biomed Res Int. 2019 2019/October/31;2019:5953619. doi:10.1155/2019/5953619.
   PubMed Web of Science ®Google Scholar
• Lee LH, Cavalcanti MS, Segal NH, Hechtman JF, Weiser MR, Smith JJ, Garcia-Aguilar J, Sadot E, Ntiamoah P, Markowitz AJ, et al. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Mod Pathol: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 2016;29(11):1433–1442. doi:10.1038/modpathol.2016.139.
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science (New York, NY). 2012;337(6102):1678–1684. doi:10.1126/science.1224922.
   Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science (New York, NY). 2011 2011/March/26;331:1565–1570. doi:10.1126/science.1203486.
   Google Scholar
• Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, et al. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol. 2013;14(4):R34. doi:10.1186/gb-2013-14-4-r34.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Bencivenga L, Poto R, Pecoraro A, Shamji MH, Rengo G. The emerging role of T follicular helper (TFH) cells in aging: influence on the immune frailty. Ageing Res Rev. 2020 2020/April/29;61:101071. doi:10.1016/j.arr.2020.101071..
   PubMed Web of Science ®Google Scholar
• Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, Förster R. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. 2000 [2000/December/06];192(11):1545–1552. doi:10.1084/jem.192.11.1545.
   PubMed Web of Science ®Google Scholar
• Crotty S. A brief history of T cell help to B cells. Nat Rev Immunol. 2015 [2015/February/14];15(3):185–189. doi:10.1038/nri3803.
   PubMed Web of Science ®Google Scholar
• Ma CS, Deenick EK. Human T follicular helper (Tfh) cells and disease. Immunol Cell Biol. 2014 [2013/October/23];92(1):64–71. doi:10.1038/icb.2013.55.
   PubMed Web of Science ®Google Scholar
• Shi W, Dong L, Sun Q, Ding H, Meng J, Dai G. Follicular helper T cells promote the effector functions of CD8+ T cells via the provision of IL-21, which is downregulated due to PD-1/PD-L1-mediated suppression in colorectal cancer. Exp Cell Res. 2018 [2018/September/12];372(1):35–42. doi:10.1016/j.yexcr.2018.09.006.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, ALLAVENA P, SICA A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002/October/29 2002;23(11):549–555. doi:10.1016/S1471-4906(02)02302-5.
   PubMed Web of Science ®Google Scholar
• Murray PJ, Allen JE, Biswas SK, Fisher E, Gilroy D, Goerdt S, Gordon S, Hamilton J, Ivashkiv L, Lawrence T, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20. doi:10.1016/j.immuni.2014.06.008.
   PubMed Web of Science ®Google Scholar
• Ge P, Wang W, Li L, Zhang G, Gao Z, Tang Z, Dang X, Wu Y. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of colorectal cancer. Biomed Pharmacother = Biomedecine & Pharmacotherapie. 2019 2019/July/28;118:109228. doi:10.1016/j.biopha.2019.109228.
   PubMed Web of Science ®Google Scholar
• Malesci A, Bianchi P, Celesti G, Basso G, Marchesi F, Grizzi F, Di Caro G, Cavalleri T, Rimassa L, Palmqvist R, et al. Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. Oncoimmunology. 2017;6(12):e1342918. doi:10.1080/2162402x.2017.1342918.
   PubMed Web of Science ®Google Scholar
• Reichman H, Karo-Atar D, Munitz A. Emerging roles for eosinophils in the tumor microenvironment. Trends in Cancer. 2016 [2017/July/26];2(11):664–675. doi:10.1016/j.trecan.2016.10.002.
   PubMed Web of Science ®Google Scholar
• Prizment AE, Vierkant RA, Smyrk TC, Tillmans LS, Lee JJ, Sriramarao P, Nelson HH, Lynch CF, Thibodeau SN, Church TR, et al. Tumor eosinophil infiltration and improved survival of colorectal cancer patients: iowa women’s health study. Mod Pathol: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 2016;29(5):516–527. doi:10.1038/modpathol.2016.42.
   PubMed Web of Science ®Google Scholar
• Sakkal S, Miller S, Apostolopoulos V, Nurgali K. Eosinophils in Cancer: favourable or Unfavourable? Curr Med Chem. 2016 2016/January/21;23:650–666. doi:10.2174/0929867323666160119094313.
   PubMed Web of Science ®Google Scholar
• Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482–491. doi:10.1038/onc.2009.356.
   PubMed Web of Science ®Google Scholar
• Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K,  Jensen BV, Hole KH, Seierstad T, Redalen KR, et al. Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. Br J Cancer. 2018 2018/April/27;118:1322–1328. doi:10.1038/s41416-018-0085-y.
   PubMed Web of Science ®Google Scholar
• Zhu H, Shan Y, Ge K, Lu J, Kong W, Jia C. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol (Dordrecht). 2020; 2020/August/17. doi:10.1007/s13402-020-00552-2.
   Web of Science ®Google Scholar
• Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, Klco JM, Helton NM, O’Laughlin M, Fronick CC,et al. Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med. 2018 2018/November/01;379:2330–2341. doi:10.1056/NEJMoa1808777.
   PubMed Web of Science ®Google Scholar
• Wu S, He H, Liu H, Cao Y, Li R, Zhang H, Li H, Shen Z, Qin J, Xu J. C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. Oncoimmunology. 2018;7(6):e1433517. doi:10.1080/2162402x.2018.1433517.
   PubMed Web of Science ®Google Scholar
• Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, Xiong B. M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22/PI3K/AKT signaling. Onco Targets Ther. 2019 2019/May/23;12:3051–3063. doi:10.2147/ott.S198126.
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Pai R, Ferrando RE, Hötzel K, Le T, Ross J, Carano R, D’Souza A, Qing J, Mohtashemi I, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene. 2008;27(1):85–97. doi:10.1038/sj.onc.1210623.
   PubMed Web of Science ®Google Scholar
• Wu W, Cao J, Ji Z, Wang J, Jiang T, Ding H. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer. Oncotarget. 2016 2016/November/12;7:81144–81155. doi:10.18632/oncotarget.13214.
   PubMedGoogle Scholar
• Liu Z, Dai W, Jiang L, Cheng Y. Over-expression of LGR5 correlates with poor survival of colon cancer in mice as well as in patients. Neoplasma. 2014 [2013/September/26];61(2):177–185. doi:10.4149/neo_2014_016.
   PubMed Web of Science ®Google Scholar
• Stanisavljevic L, Myklebust MP, Leh S, Dahl O. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer. Acta Oncologica (Stockholm, Sweden). 2016 2016/July/21;55:1425–1433. doi:10.1080/0284186x.2016.1201215.
   PubMed Web of Science ®Google Scholar
• Adamsen BL, Kravik KL, Clausen OP, De AngelisPM. Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol. 2007. 31:1491–1500. 2007/November/06
   PubMed Web of Science ®Google Scholar
• Marisa L, de Reynies A, Duval A, Selves J, Pierre Gaub M, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Guenot M, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013 2013/May/24;10:e1001453. doi:10.1371/journal.pmed.1001453.
   PubMed Web of Science ®Google Scholar
• Allen WL, Dunne PD, McDade S, Scanlon E,  Loughrey M,  Coleman H,  McCann C,  McLaughlin K,  Nemeth Z,  Syed N, et al. Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy. JCO Precisi Oncol. 2018. 2018. 2018/August/09 doi:10.1200/po.17.00241.
   Google Scholar
• Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile J-F, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, et al. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. Eur J Cancer (Oxford, England: 1990). 2017 2017/March/12;76:68–75. doi:10.1016/j.ejca.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy–analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004 2004/February/13;20:307–315. doi:10.1093/bioinformatics/btg405.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015 [2015/March/31];12(5):453–457. doi:10.1038/nmeth.3337.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res: An Official Journal of the American Association for Cancer Research. 2004 2004/November/10;10:7252–7259. doi:10.1158/1078-0432.Ccr-04-0713.
   PubMed Web of Science ®Google Scholar
• Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. Biom J. 2010 2009/November/26;52:70–84. doi:10.1002/bimj.200900028.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics-a Journal of Integrative Biology. 2012;16:284–287. doi:10.1089/omi.2011.0118.
   PubMed Web of Science ®Google Scholar
• Tibshirani R. Regression shrinkage selection via the LASSO. J R Stat Soc Series B Stat Methodol. 2011;73:273–282.
   Google Scholar